Vyriad, Inc.
Vyriad is a clinical-stage biotechnology company dedicated to developing targeted genetic therapies using engineered viruses. Founded by Mayo Clinic scientists and based in Rochester, Minnesota, Vyriad specializes in engineering virus platforms for in vivo gene therapies, gene editing, and oncolytic virotherapy. The company collaborates with leading medical institutions and pharmaceutical companies to advance cancer treatments and other genetic therapies worldwide. Vyriad's approach emphasizes a cross-functional, holistic development process integrating preclinical, manufacturing, and clinical expertise, with ongoing clinical trials in multiple cancer indications and strategic collaborations with partners like Regeneron and Novartis.
Industries
Nr. of Employees
medium (51-250)
Vyriad, Inc.
2900 37th Street NW, Building 110, Rochester, MN 55901
Products
VSV-based armed and trackable oncolytic virus (clinical-stage)
A vesicular stomatitis virus-derived oncolytic construct engineered for systemic or intratumoral administration, designed to express immunomodulatory payloads and be trackable by imaging.
Measles-based oncolytic virus encoding NIS (clinical-stage)
A measles virus-derived oncolytic construct engineered to express a sodium iodide symporter reporter for intravesical or direct tumor administration and imaging.
VSV-based armed and trackable oncolytic virus (clinical-stage)
A vesicular stomatitis virus-derived oncolytic construct engineered for systemic or intratumoral administration, designed to express immunomodulatory payloads and be trackable by imaging.
Measles-based oncolytic virus encoding NIS (clinical-stage)
A measles virus-derived oncolytic construct engineered to express a sodium iodide symporter reporter for intravesical or direct tumor administration and imaging.
Services
Co-development and strategic alliance services to jointly advance viral platforms and combination regimens with academic and industry partners.
GMP-compliant manufacturing operations for production of viral vectors and oncolytic viruses to support clinical trials.
End-to-end clinical operations including trial design, multicenter coordination, site management and safety/pharmacodynamic monitoring for oncolytic virus studies.
Preclinical efficacy and safety testing, comparative oncology studies, and development/validation of immuno-monitoring assays.
Co-development and strategic alliance services to jointly advance viral platforms and combination regimens with academic and industry partners.
GMP-compliant manufacturing operations for production of viral vectors and oncolytic viruses to support clinical trials.
End-to-end clinical operations including trial design, multicenter coordination, site management and safety/pharmacodynamic monitoring for oncolytic virus studies.
Preclinical efficacy and safety testing, comparative oncology studies, and development/validation of immuno-monitoring assays.
Expertise Areas
- Oncolytic virotherapy development
- Viral vector engineering for targeted in vivo delivery
- In vivo cell engineering (in vivo CAR-T approaches)
- Clinical trial management for viral therapeutics
Key Technologies
- Vesicular stomatitis virus (VSV)-based oncolytic platforms
- Measles virus-based oncolytic platforms
- Lentiviral vector engineering for targeted transduction
- Reporter gene imaging (NIS/radioisotopic reporters)
News & Updates
Vyriad representatives attended and presented research on targeted in vivo CAR gene delivery and oncolytic virotherapy.
Vyriad leadership presented on in vivo cell engineering and gene therapy progress.
Collaboration to develop in vivo CAR-T cell therapies leveraging Vyriad’s viral platform.
A study developed a measles virus-vectored vaccine inducing high neutralizing antibody responses against COVID-19.
Research highlights early signs of oncolytic virus therapy in lymphoma patients.
Vyriad, founded by Mayo Clinic researchers, is advancing targeted oncolytic virus therapies.
Vyriad representatives attended and presented research on targeted in vivo CAR gene delivery and oncolytic virotherapy.
Vyriad leadership presented on in vivo cell engineering and gene therapy progress.
Collaboration to develop in vivo CAR-T cell therapies leveraging Vyriad’s viral platform.
A study developed a measles virus-vectored vaccine inducing high neutralizing antibody responses against COVID-19.
Research highlights early signs of oncolytic virus therapy in lymphoma patients.
Vyriad, founded by Mayo Clinic researchers, is advancing targeted oncolytic virus therapies.